Stock News

Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.

The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.

Its Texas subsidiary would pay PsyLabs the milestones for the first drug candidate; the binding terms lapse without a definitive agreement by Nov. 30.

The Sept. 28 vote approved articles changes, preferred allotments and market repurchases; a possible IPO still needs an FCA-approved prospectus.

The four-year line starts at SOFR plus 175 basis points and can back utility and equipment obligations with letters of credit.

The 40-patient tipelukast study missed its week-24 liver-fat and triglyceride comparisons, although secondary HDL measures improved.

The Manitoba reserve plan adds two years to Snow Lake's schedule and forecasts 185,000 gold ounces a year on average through 2030.

Under current budgets, Fulcrum expects a £2.5M loan draw and £500K equity subscription to fund its pilot and first Teck-Hughes programme.

The AIM software group ended a process begun in March and reported £6.3 million revenue for the six months to July 31.

The other two Lorado holes showed no significant anomalous radioactivity; Gulch drilling is planned for 900 metres in three holes.

A September QIAGEN safety document lists 13 bacterial targets and 18 resistance markers for the newly cleared assay.

The Los Nanos assays include mineralization beyond the existing model, but the sector has no reserves and remains outside the mine plan.

The Western Australian deposit now contains 526,000 indicated ounces, with the larger estimate set for a Sandstone study due in the December quarter.

The Sept. 24 verdict awards US$90 million plus interest the court will determine; post-trial proceedings and a possible appeal remain.

The Sept. 26 first pour came before the original second-quarter 2027 schedule; the oxide circuit is targeted for commercial production in late 2026.

FDA cleared the weekly basal insulin for adults with type 2 diabetes on Sept. 24; Lilly expects the U.S. pen in the coming months.

An unnamed AI lab committed to enter a separate ten-year Barber Lake lease after Fluidstack's term; first rent commencement is expected in the fourth quarter of 2026.

Hole TAK-26-16 includes 229 grams per tonne gold over 0.65 metre, with results from four Phase III holes pending.

The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

SIDEX and NQ Mining Investment lead the flow-through sale, priced at C$0.145 a share and expected to close about Sept. 29.

The Sept. 25 weekly update lists 288.1 BTC mined and zero net coins added; Friday's Nasdaq close predates the post.

COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.

The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.

Its July placement issued 35.98 million shares and matching warrants, while the latest notice disclosed $334,577 in finder fees.

Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.

In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.

The Swiss cybersecurity group expects Oct. 2 to be the last session for its existing ADSs and Class B shares before a planned WISeQey listing.

The Swedish developer says the deal could bring up to €1.165B, but its published terms do not separate the upfront payment from later milestones.

The partners cited FDA discussions over Phase 2 evidence and kept a randomized Phase 3 lung cancer trial enrolling.

The US$3.65 units carry half a warrant each, and Goldgroup has not assigned the proceeds to specific projects.

The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.

The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.

Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.

Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.

A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.

It counted 180 new customer contracts through Sept. 23 but gave no schedule for recognizing their value as revenue.

Adjusted EPS beat BlackBerry's June outlook, while the company forecast a sharp licensing revenue decline in the next quarter.

Both doses passed a vision noninferiority test against ranibizumab; higher rates of retinal complications await detail.

The new Phase 3 study shifts its primary measure to lung function after an earlier miss, but aTyr says it needs more money to run it.